Fischer Medical Ventures
- Market cap
- ₹ 1,639 Cr.
- P/E
- 76.3x
- P/B
- 4.06x
- 52-week range
- 21.78 – 121.7
- ROE
- 9%
- ROCE
- 11%
- Dividend yield
- 0.2%
- Debt / equity
- 0.28
- Sector
- Healthcare Equipment & Supplies
- Industry
- Medical Equipment & Supplies
- Listed on
- NSE, BSE
About
Fischer Medical Ventures Limited is an India-based company. The Company specializes in trading and manufacturing of magnetic resonance imaging (MRI) systems. It is engaged in the development of advanced medical diagnostic and imaging technologies, through its wholly owned subsidiary, Time Medical International Ventures (India) Private Limited. It comprises a manufacturing facility that can produce 160 MRI machines per year. It provides a comprehensive range of healthcare solutions across various specialties, namely Ophthalmology, Cardiology, Oncology, Dentistry, Neurology, Mental Health, and Point of Care. The Company's products include PICA, MONA, EMMA, NEONA, and NOVA.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Medical Equipment & Supplies: 25 companies →Fischer Medical Ventures against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)76.3 against a typical 28.7: pricier than most peers (1st = cheapest).23rd of 25
- Sales growth+249.5% against a typical +21.5% from a year earlier.2nd of 18
- Profit growth−22% against a typical +13.4% from a year earlier.12th of 16
- Share price, 3 months−26.3% against a typical −7.9%.19th of 23
- Size₹ 1,639 Cr. market value against a typical ₹ 238.1 Cr. (1st = largest).3rd of 24
Latest announcements
Exchange filings and their impact on the company.
- Fischer seeks shareholder nod for Rs 350 crore secured NCD and Rs 1,000 crore borrowing limit.
Fischer Medical Ventures has dispatched a postal ballot notice dated 14 October 2026 seeking shareholder approval for seven resolutions. The key proposals back a proposed Rs 350 crore senior secured NCD issue with a floating charge over two key subsidiaries, pledge of 100% of their shares, promoter share pledge for 2.5x cover, and Rs 350 crore corporate guarantees each from FMV Holdings and Mercatus Capital, plus raising the overall borrowing limit to Rs 1,000 crore. If approved, the company can proceed to raise the debt for expansion and working capital, sharply increasing leverage and asset encumbrance.
Board meetings
Results dates and other board meetings. Full calendar
| Details | ||
|---|---|---|
| 14 Aug 2026 | Financial Results | To consider and approve the financial results for the period ended Jun 30, 2026 |
| 29 May 2026 | Financial Results/Dividend | To consider and approve the financial results for the period ended March 31, 2026 and dividend |
| 30 Jan 2026 | Financial Results | To consider and approve the financial results for the period ended December 31, 2025 |
| 28 Oct 2025 | Financial Results/Other business matters | To consider and approve the financial results for the period ended September 30, 2025 and other business matters |
| 14 Aug 2025 | Financial Results | To consider and approve the unaudited financial results for the period ended Jun 30, 2025 |
| 28 Jul 2025 | Stock Split | To consider stock split of equity shares and allied items |
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 21 | 10 | 40 | 12 | 49 | 23 | 86 | 101 | 98 | 82 |
| Expenses | 0 | 18 | 10 | 39 | 11 | 47 | 19 | 70 | 80 | 101 | 71 |
| Operating Profit | 0 | 3 | −0 | 1 | 0 | 3 | 4 | 16 | 22 | −4 | 11 |
| OPM % | — | 12.1% | −2.1% | 1.3% | 3.2% | 5.1% | 17% | 18.8% | 21.3% | −3.9% | 13.7% |
| Other Income | 0 | 0 | 1 | 0 | 0 | 0 | 7 | 2 | 1 | 1 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 4 | 4 |
| Depreciation | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 0 | 3 | 0 | 0 | 0 | 2 | 10 | 17 | 21 | −8 | 8 |
| Tax % | — | 6.2% | 271.4% | −38.1% | 350% | 26% | 51.6% | 19.5% | 9.2% | 64% | 51.6% |
| Net Profit | 0 | 3 | −0 | 0 | −0 | 1 | 5 | 14 | 19 | −12 | 4 |
| EPS in Rs | 0 | 0.05 | 0 | 0.01 | −0.01 | 0.02 | 0.07 | 0.21 | 0.3 | −0.19 | 0.06 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 1,097%
- TTM
- 196%
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 820%
- TTM
- 286%
- 10 Years
- 71%
- 5 Years
- 33%
- 3 Years
- 60%
- TTM
- —
- 10 Years
- —
- 5 Years
- —
- 3 Years
- 6%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Fischer Medical Ventures | ₹ 26.35 | ₹ 1,639 Cr. | 76.3x | 4.1x | 9% | — |
| Asian Paints | ₹ 2,305.00 | ₹ 2,21,095 Cr. | 58.1x | 12.1x | 21.2% | 12.4% |
| Solar Industries India | ₹ 18,320.00 | ₹ 1,65,778 Cr. | 99.6x | 26.6x | 31.4% | 17.7% |
| Pidilite Industries | ₹ 1,514.00 | ₹ 1,54,107 Cr. | 64.8x | 14.7x | 23.8% | 16.9% |
| SRF | ₹ 2,309.00 | ₹ 68,444 Cr. | 44.6x | 6.1x | 13.8% | 11.6% |
| Linde India | ₹ 5,697.00 | ₹ 48,586 Cr. | 110.5x | 14.2x | 13.6% | 21.7% |
Management
- Ravindran Govindan
- Executive Chairman of the Board, Managing Director
- Vivek Balasubramanian
- Chief Financial Officer
- Shankar Varadharajan
- Chief Operating Officer
- Balaji Gandla
- Compliance Officer, Company Secretary
- Svetlana Rao Raviwada
- Whole-Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.